Karyopharm (KPTI) Q2 2025 Profits Transcript

DATE

Aug. 11, 2025 at 8 a.m. ET

CALL PARTICIPANTS

• Leader Government Officer — Richard A. Paulson
• Leader Clinical Officer — Reshma Rangwala
• Leader Industrial Officer — Sohanya Cheng
• Leader Monetary Officer — Lori A. Macomber

TAKEAWAYS

• XPOVIO Internet Product Income — $29.7 million, representing a 6% building up in comparison to the similar quarter in 2024.
• Overall Income — $37.9 million, down from $42.8 million within the prior-year duration, essentially because of $6 million in nonrecurring license income identified in Q2 2024.
• Royalties — $1.6 million, up 28% 12 months over 12 months, reflecting larger world call for thru companions Menarini and Antengene.
• Gross-to-Internet Provisions — 26.8% for XPOVIO, down from 29.3% in Q2 2024 and from 45% in Q1, reflecting go back to ancient ranges following an odd spike closing quarter.
• R&D Bills — $32.8 million, representing a fifteen% lower in comparison to $38.4 million because of headcount and contractor discounts plus decrease scientific trial spending in a couple of myeloma.
• SG&A Bills — $28.5 million, down 8% as opposed to $31.1 million following the have an effect on of prior value relief tasks.
• Hobby Expense — $11.2 million, upper than $8.9 million closing 12 months, with the rise tied to refinancing that was once handiest in part mirrored in Q2 2024.
• Internet Loss (GAAP) — $37.3 million, or $4.32 in keeping with proportion, incorporating $11.2 million in passion expense and ~$2 million in noncash losses referring to warrant and spinoff remeasurement.
• Internet Loss from Operations — $24.5 million, offering perception into core running efficiency unique of non-operational fees.
• Money, Equivalents, and Investments — $52 million as of quarter finish, down from $109.1 million at December 31, 2024.
• 2025 Complete-12 months Income Steering — $140 million to $155 million in overall income, with U.S. XPOVIO web product income anticipated at $110 million to $120 million.
• 2025 Bills Steering — Blended R&D and SG&A between $240 million and $250 million.
• Staff Aid — About 20% of body of workers reduce in early July, projected to scale back annual spend through ~$13 million in 2026.
• Debt and Liquidity — Liquidity anticipated to fund operations into January 2026, however handiest thru October 15, 2025, for senior convertible notes after accounting for the $24.5 million notes adulthood and $25 million minimal liquidity covenant.
• SENTRY Trial Milestone — Affected person screening for Section III SENTRY in JAK-naive myelofibrosis is anticipated to near this week, with top-line knowledge expected in March 2026.
• SENTRY Trial Initial Protection — Within the blinded cohort of 61 sufferers, extrapolated Grade 3/4 anemia charge is ~26% as opposed to 37% ancient with ruxolitinib, and discontinuations for treatment-emergent hostile occasions are 5%-7% for the mix as opposed to 6%-11% with ruxolitinib traditionally.
• SENTRY-2 Trial Replace — Enrollment to increase after of completion of SENTRY, with standards to incorporate all sufferers with platelet counts above 50,000.
• Endometrial Most cancers Trial (XPORT-EC-042) — Enrollment is progressing incessantly, without a specific enrollment figures equipped; top-line knowledge centered for center of 2026.
• Height Income Attainable — Control estimates selinexor in myelofibrosis may achieve as much as $1 billion every year within the U.S. on my own.
• Industrial Release Preparedness — 75% of surveyed physicians intend to undertake a mixture remedy for myelofibrosis if authorized, with 80% overlap in network prescribers for myelofibrosis and a couple of myeloma facilitating fast uptake.

Desire a quote from a Motley Idiot analyst? Electronic mail [email protected]

RISKS

• CEO Paulson mentioned, “We’re running in a duration of economic constraints with a near-term debt adulthood in October. We’re actively engaged with our lenders and advisers to give a boost to our liquidity and maximize price.”
• CFO Macomber famous, “We’re going to be enough to fund our deliberate operations to the October 15 adulthood of our senior convertible notes.” and “We think that our liquidity is enough to fund our deliberate operations into January 2026,” highlighting tight money runway and debt refinancing wishes.
• Hobby expense rose to $11.2 million for the quarter because of prior refinancing, elevating expense power relative to prior classes.
• “Enrollment on this trial has been slower than expected,” in keeping with Rangwala, indicating demanding situations in trial enrollment dynamics and leading to not on time timelines for initial knowledge.

SUMMARY

Karyopharm Therapeutics (KPTI +6.39%) reported larger XPOVIO web product income however decrease overall income on diminished one-time licensing contributions in Q2 2025. The corporate finished primary enrollment milestones for its lead Section III SENTRY trial in myelofibrosis, with initial blinded protection knowledge indicating probably advanced tolerability for the selinexor plus ruxolitinib aggregate in comparison to ruxolitinib on my own. Control guided for U.S. XPOVIO web product income of $110 million to $120 million for the entire 12 months and highlighted an important alternative in myelofibrosis, estimating height U.S. annual income possible as much as $1 billion, pending a hit Section III results and regulatory approval. Cautious money and expense control continues, with notable year-over-year discounts in R&D and SG&A, however the corporate faces an forthcoming debt adulthood and has engaged advisers to hunt strategic and financing possible choices.

• Blinded extrapolated protection knowledge from SENTRY recommend grade 3/4 anemia and discontinuation charges with selinexor plus ruxolitinib could also be not up to ancient ruxolitinib controls, whilst absolute hostile occasion charges stay prime and in line with expectancies for this affected person inhabitants.
• XPOVIO utilization is described as increasing the world over, with royalty revenues emerging 28% reflecting broader world get right of entry to and business partnerships.
• Finalization of SENTRY enrollment lets in the corporate to increase inclusion for the SENTRY-2 monotherapy find out about, which up to now struggled with sluggish recruitment because of overlapping website participation and eligibility restrictions.
• Control showed that required twin antiemetic use within the SENTRY trial’s early cycles could also be using advanced gastrointestinal tolerability, a protocol alternate from prior research.
• Royalty, milestone, and web gross sales from companions supply incremental income streams past U.S. operations, despite the fact that the primary business consideration stays on XPOVIO and expected myelofibrosis launches.
• Corporate maintains self belief in Section III trial endpoints following prior alignment with the U.S. FDA, without a further regulatory comments since Q3 2024.

INDUSTRY GLOSSARY

• JAK-naive: Refers to sufferers with myelofibrosis who’ve no longer up to now won Janus kinase (JAK) inhibitor remedy.
• SVR35: Spleen Quantity Aid of a minimum of 35%, a regular scientific efficacy endpoint in myelofibrosis trials.
• TSS: Overall Symptom Ranking, a scientific measure assessing symptom burden in myelofibrosis.
• MMRM: Combined Fashions Repeated Measure, a complicated statistical research approach for longitudinal trial endpoints.
• TEAE: Remedy-Emergent Antagonistic Match, any hostile occasion going on after medicine initiation in a scientific trial.
• SINE: Selective Inhibitor of Nuclear Export, the drug magnificence to which selinexor belongs, inhibiting the XPO1 protein to vary most cancers mobile survival.
• p53 wild kind: Describes tumors through which the TP53 gene isn’t mutated, which is regularly referenced as a biomarker in most cancers research.
• 340B reductions: U.S. federal program reductions equipped through drug producers to eligible well being care organizations and coated entities.

Complete Convention Name Transcript

Brendan Twohig Sturdy: Just right morning. Thanks for becoming a member of us on these days’s convention name to speak about Karyopharm’s 2d Quarter 2025 monetary effects and up to date corporate growth. We issued a press unencumber this morning detailing our monetary effects for the second one quarter of 2025. This unencumber, at the side of a slide presentation that we will be able to reference right through our name these days are to be had on our web page. For these days’s name, as observed on Slide 2, I am joined through Richard, Reshma, Sohanya and Lori, who’ll supply an replace on our effects for the second one quarter of 2025 and speak about contemporary scientific trends.

Sooner than we start our formal feedback, I will remind you that quite a lot of remarks we will be able to make these days represent forward-looking statements for functions of the protected harbor provisions below the Personal Securities Litigation Reform Act of 1995 as defined on Slide 3. Precise effects would possibly fluctuate materially from the ones indicated through those forward-looking statements on account of quite a lot of essential elements, together with the ones mentioned within the Possibility Components phase of our most up-to-date Shape 10-Q or 10-Ok on document with the SEC and in different filings that we would possibly make with the SEC sooner or later. Any forward-looking statements constitute our perspectives as of these days handiest.

Whilst we would possibly elect to replace those forward-looking statements sooner or later sooner or later, we in particular disclaim any legal responsibility to take action although our perspectives alternate. Subsequently, you must no longer depend on those forward-looking statements as representing our perspectives as of any later date. I will now flip the decision over to Richard. Please flip to Slide 4.

Richard A. Paulson: Thanks, Brendan, and thanks concerned with becoming a member of us these days for Karyopharm’s Q2 2025 income name. Sooner than we start, as defined on Slide 5, I need to deal with a subject matter this is at the minds of our workers, our companions and our buyers. We’re running in a duration of economic constraints with a near-term debt adulthood in October. We’re actively engaged with our lenders and advisers to give a boost to our liquidity and maximize price. Importantly, the basics of our trade stay sturdy with a winning multi-myeloma business group that gives us with a cast basis that we will be able to construct on with 2 probably transformative Section III readouts anticipated over the following three hundred and sixty five days.

Those trials goal illnesses the place sufferers have few medicine choices and there is a chance to toughen on current treatments. In accordance with the energy of our knowledge to this point, we imagine we have now the prospective to redefine the usual of deal with those sufferers. That is the price that we’re construction in opposition to and what drives our self belief within the long-term trajectory of the corporate. With that, let’s get into our effects for the quarter, the place we delivered cast business effects and made thrilling growth in opposition to enrolling our pivotal Section III trials in myelofibrosis and endometrial most cancers.

I’m happy to record that we predict to near new affected person screening this week in our Section III SENTRY trial in sufferers with JAK- naive myelofibrosis. It is a primary milestone that may be a results of a few years of exhausting paintings and determination from folks all through our group and I thank all of our groups. We very much thank the sufferers and scientific trial websites which might be taking part in SENTRY. Importantly, SENTRY can be our first Section III trial readout the place we make the most of a decrease dose of selinexor blended with antiemetics right through the primary 2 cycles of medicine to toughen the tolerability of selinexor as we paintings to give a boost to the affected person revel in.

Via our sturdy scientific trial execution, we’re seeing the advantages of either one of those elements within the initial blinded protection knowledge that Reshma will evaluation to this point. We’re eagerly expecting peak line knowledge in March of 2026. Turning to Slide 6. Finishing enrollment in our Section III SENTRY trial is crucial step on our over 7-year adventure to show the position that XPO1 inhibition would possibly play in sufferers with myelofibrosis. The Section III trial caps a rising frame of proof that has persistently demonstrated the possibility of XPO1 in myelofibrosis.

We’re positive about the possibility of selinexor plus ruxolitinib to redefine the usual of deal with sufferers residing with this illness and pending certain knowledge, the transformational alternative this represents for our group. As defined on Slide 7, given the chance to toughen the usual of care, main KOLs, together with Dr. John Mascarenhas from Mount Sinai, who’s the essential investigator for SENTRY proceed to spotlight the will for brand new medicine choices for sufferers with myelofibrosis. The intensity and sturdiness of reaction that Dr. Mascarenhas discussed in a up to date interview with a affected person advocacy group, performs to the energy of selinexor.

After all, as proven on Slide 8, we estimate the height income possible for selinexor in myelofibrosis is as much as roughly $1 billion every year within the U.S. on my own and imagine that business uptake could be fast. We’re very desperate to convey this mix remedy to the marketplace, pending the result of our knowledge and long run regulatory approvals. Now I would like to show the decision over to Reshma.

Reshma Rangwala: Thanks, Richard. I will be able to be sharing new blinded initial protection knowledge with you these days from our Section III SENTRY trial that can make stronger the potential for the mix of selinexor plus ruxolitinib which could have a equivalent, if no longer extra favorable protection profile than ruxolitinib on my own. Sooner than I am getting into the brand new knowledge, let’s evaluation why we imagine selinexor as an XPO1 inhibitor is a rational mechanism to guage in sufferers with myelofibrosis, beginning on Slide 10. Selinexor prevents the nuclear export of quite a lot of proteins and messenger RNA molecules, thus inhibiting each JAK and non-JAK pathways.

The latter, which incorporates the nuclear localization and activation of p53, crucial tumor suppressor in myelofibrosis, for the reason that roughly 95% of myelofibrosis sufferers are p53 wild kind. As Richard indicated, we imagine that the mix of selinexor plus ruxolitinib has the prospective to determine a brand new medicine paradigm for myelofibrosis sufferers through addressing every of the 4 key pillars of this illness as defined on Slide 11. Whilst no assurances may also be given, our self belief continues to fortify as we obtain and evaluation further knowledge, together with up to date blinded protection knowledge that I will be able to be reviewing in a while.

To set the level, there was a loss of new medicine choices for the reason that JAK inhibitors are the one authorized magnificence of treatments. Ruxolitinib has been the usual of deal with over 13 years. As the prospective first aggregate remedy in myelofibrosis, selinexor plus ruxolitinib could be a handy all oral remedy that the myelofibrosis network has obviously indicated passion in adopting given the fast, deep and sturdy spleen discounts and symptom development noticed from the Section I find out about. Let’s now center of attention at the 4 key hallmarks in myelofibrosis. First, spleen quantity relief. I feel this is a very useful reminder that handiest roughly 1/3 of sufferers accomplished a spleen quantity relief of more than 35% with ruxolitinib on my own.

Our Section I knowledge means that the mix may greater than double the SVR35 charge with sturdy responses additionally observed. 2d is symptom development. Information from our Section I trial of selinexor together with ruxolitinib confirmed a mean 18.5 level development in absolute TSS at week 24, which means this mix may supply a significant development over the 11 to 14-point development accomplished through sufferers on ruxolitinib as noticed within the Section III MANIFEST-2 and TRANSFORM-1 trials. 3rd is hemoglobin stabilization and transfusion burden.

The information that we introduced in June at EHA display upper hemoglobin ranges, decrease transfusion burden in a lot decrease charges of all grade in grade 3 plus anemia in myelofibrosis sufferers up to now handled with JAK inhibitor treatments who have been randomized to selinexor in comparison to the doctor’s selection arm which incorporated retreatment with the JAK inhibitor treatments, together with ruxolitinib. Fourth is illness amendment. There may be minimum proof of illness amendment with JAK inhibitors.

Information noticed from selinexor monotherapy research in a pretreated myelofibrosis inhabitants in addition to our Section I aggregate knowledge in JAK inhibitor naive myelofibrosis, recommend significant discounts in key cytokines which might be essential to myelofibrosis pathogenesis, symptom construction and anemia in addition to enhancements in bone marrow fibrosis will increase in erythroid progenitors and mutational burden. Turning to Slide 12. We’re happy that our Section III SENTRY trial can be last new sufferers screening this week. Importantly, founded upon an preliminary evaluation of the baseline traits of the sufferers enrolled to this point, they’re consultant of the meant affected person inhabitants.

One notable function is the baseline TSS, which when aside from fatigue, would possibly in the end be upper than different Section III trials, crucial pattern that can recommend that our trial might be smartly situated to record a better development in absolute TSS. On this new generation of aggregate treatments, there were demanding situations demonstrating significant symptom development above and past ruxolitinib. Based totally upon learnings from different trials, we imagine we have now optimized SENTRY for good fortune. First, we modified the co-primary endpoint of TSS50 to absolute TSS, a extra delicate approach wherein to discover significant symptom development above and past ruxolitinib. 2d, we have now excluded the fatigue area and the main research of ABSOLUTE TSS in alignment with the U.S.

FDA because of the trouble in correctly assessing adjustments on this symptom. We’re on no account the primary to exclude fatigue. In truth, each the pivotal trials that ended in ruxolitinib and fedratinib approvals additionally excluded fatigue of their TSS50 analyses. It is also essential to remember the fact that all of our research have excluded fatigue and symptom research, together with our Section I find out about comparing the mix of selinexor and ruxolitinib in addition to MSO35, which evaluated selinexor as a monotherapy in up to now handled MF sufferers. After all, absolute TSS within the Section III SENTRY trial can be analyzed the usage of the combined fashions repeated measure means or MMRM.

This differs from our Section I, which given the restrictions in pattern dimension may handiest review the imply or moderate alternate at week 24. MMRM is seen as a extra delicate and probably extra powerful approach wherein to research absolute TSS. The co-primary endpoints in SENTRY are SVR35 in absolute TSS, that are examined sequentially. Probably the most key secondary and exploratory endpoints that may also be analyzed come with progression-free survival, total survival, hemoglobin stabilization, variant allele frequency relief, development in bone marrow fibrosis and adjustments in cytokine ranges.

Now let’s evaluation the encouraging initial blinded combination protection knowledge from this trial, as those are initial knowledge please remember the fact that those knowledge will not be reflective of the trial’s precise peak line effects. The information on Slides 13 and 14 are from the primary 61 sufferers that enrolled within the Section III portion of the SENTRY that experience now been adopted for a mean of over three hundred and sixty five days. Those sufferers have been incorporated within the effectively handed futility research carried out to start with of the 12 months.

Whilst handiest contributors of the DSMB had get right of entry to to the unblinded efficacy and protection knowledge from those sufferers, we have now endured to trace the protection occasions through the years and took a snapshot of the blinded protection knowledge from those 61 sufferers on July 1, 2025, which endured to appear favorable. Let’s get started through reviewing the hostile occasion abstract at the left aspect of Slide 13. The information at the 61 sufferers proven within the desk come with sufferers randomized to both the mix of selinexor plus ruxolitinib or ruxolitinib in a 2:1 ratio. As a result of those are blinded knowledge, we have no idea the charges through every arm.

The second one and 3rd columns give you the medicine emergent hostile occasion abstract, or TEAE abstract following a mean follow-up of greater than 7 months or three hundred and sixty five days, respectively. What you notice within the abstract is that most of the hostile occasions happen early without a significant building up in charges after the median of seven months of follow-up. To be able to toughen comparison, we then took our research one step additional. Understanding that the 61 sufferers have been randomized 2:1, we use the ancient knowledge on ruxolitinib to extrapolate the initial protection knowledge for the roughly 40 sufferers that won the mix, which is proven within the blue containers at the proper aspect of the slide.

As you’ll see, the share of sufferers that experience had a minimum of 1 TEAE is roughly 97%, very similar to what has been described for ruxolitinib. Alternatively, once we center of attention at the grade 3 plus TEAEs the extrapolated knowledge means that the speed could also be fairly decrease for sufferers at the aggregate as opposed to ruxolitinib at roughly 53% and 57%, respectively. Taking a look at severe TEAEs, the extrapolated knowledge suggests a good higher get advantages for the mix remedy than ruxolitinib. After all, the extrapolated charge of TEAEs resulting in medicine discontinuation is handiest 5% to 7% for the mix, not up to 6% to 11% vary that has been traditionally reported for ruxolitinib, which we view as an encouraging statement.

Let’s flip to the person medicine emergent hostile occasions, as proven on Slide 14. We took the similar means with those knowledge as those I simply described at the prior slide. Beginning at the left, you can see the all-grade blinded protection knowledge at the 61 sufferers with a mean follow-up of greater than 7 months and once more for greater than three hundred and sixty five days. We additionally display 2 noteworthy Grade 3/4 TEAEs on the backside left, anemia and thrombocytopenia. In line with what I described at the prior slide, we see maximum TEAEs going on inside the first 7 months of follow-up.

Further occasions are noticed with the passage of time, ensuing within the charges of TEAEs modestly larger at three hundred and sixty five days of follow-up. The quantity that excites me probably the most is the extrapolated charge of Grade 3/4 anemia at roughly 26%, the extrapolated charge of Grade 3/4 anemia for the mix is meaningfully not up to the 37% traditionally reported for ruxolitinib. And whilst the extrapolated charge of all grade nausea is upper within the aggregate arm than ruxolitinib the roughly 64% is considerably not up to the roughly 80% charge that we reported within the Section I portion of this trial. We’ve just lately introduced compelling cytokine knowledge that might give an explanation for partly the efficacy absorbed with selinexor.

As well as, Slide 15 presentations pictographs of bone marrows evaluated at baseline and at week 24 from a affected person handled with the selinexor ruxolitinib aggregate and is additional proof of the prospective illness amendment that selinexor would possibly induce in sufferers with myelofibrosis. Those knowledge have been first introduced through Dr. Harris Ali on the World Congress of Myeloproliferative Neoplasms in October of 2024. This JAK inhibitor naive myelofibrosis affected person was once handled with selinexor 60 milligrams and ruxolitinib 15 milligrams two times an afternoon as in keeping with the USPI. Because of cytopenias, the ruxolitinib dose was once reduced to suboptimal ruxolitinib doses 5 milligrams two times an afternoon beginning in cycle 2.

The affected person accomplished an SVR35 as early as week 12 and a TSS50 as early as week 8 on account of symptom relief from a baseline of 42 issues to 19.5 issues at week 8. The efficacy noticed on this affected person may also be defined partly through the significant alternate going on of their bone marrow, in particular a 46% relief in fiber density assessed through virtual pathology was once noticed at week 24 in comparison to baseline samples as was once an roughly 200% building up in erythroid progenitors that are precursors of mature crimson blood cells.

Whilst this can be a unmarried affected person revel in, the rise in erythroid progenitors may additionally give an explanation for the possibly decrease grade 3- plus anemia charges with the mix as in comparison to ancient ruxolitinib knowledge as I defined at the earlier slide. We’re very inspired about those knowledge and what it will imply for sufferers if we see one thing equivalent within the peak line ends up in the Section III SENTRY trial. In particular, it will recommend a mixture remedy that has a security profile equivalent if no longer probably higher than same old of care ruxolitinib.

For the reason that each Grade 3 plus anemia and thrombocytopenia are the similar, if no longer higher than ruxolitinib on my own, it will additionally recommend reduced blood attracts for the affected person and diminished tracking burden for physicians and well being care body of workers. I’d additionally like to supply an replace on our Section II SENTRY 2 trial, the place we’re comparing selinexor as a monotherapy in JAK inhibitor-naive myelofibrosis sufferers with reasonable thrombocytopenia. Enrollment on this trial has been slower than expected, for the reason that the majority of websites enrolling on SENTRY 2 also are enrolling sufferers into SENTRY and we have now requested websites to prioritize enrollment on SENTRY.

As well as, sufferers with platelet counts between 50,000 and 100,000 represents handiest 10% to fifteen% of all JAK-naive myelofibrosis. Now that SENTRY enrollment is finished, we plan on increasing the enrollment standards to incorporate all sufferers with platelet counts above 50,000, pending they meet all different eligibility standards. This must building up the choice of sufferers that may take part on this trial. Our prior plan was once to record initial knowledge on a subset of sufferers from SENTRY 2 within the first part of this 12 months.

Given the enrollment demanding situations and the adjustments we’re making to the enrollment standards, we now plan to record peak line knowledge from all sufferers that we join within the 60-milligram cohort of this trial in 2026. Now let’s shift our center of attention to endometrial most cancers, the place p53 wild kind is such crucial biomarker. As observed on Slide 17, sufferers with each MMR talented and TP53 wild-type tumors make up roughly 50% of all complex or recurrent endometrial most cancers circumstances, representing an excessively sizable crew. Enrollment within the export EC042 trial is progressing incessantly as observed on Slide 18, and we proceed to be expecting to record peak line knowledge in the midst of 2026.

I stay inspired with the potential for selinexor to reach clinically significant results within the repairs atmosphere for sufferers with p53 wild-type endometrial most cancers. Finally, our Section III EMN29 SPd trial is printed on Slide 20. This trial goals to show the potential for an all-oral triplet medicine possibility for a couple of myeloma sufferers that might additionally get advantages the ones present process pre- and put up T-cell enticing treatments. We think to record peak line knowledge from this event-driven trial within the first part of 2026. I will be able to now flip the decision to Sohanya.

Sohanya Cheng: Thanks, Reshma. On Slide 22, I will be able to speak about our business highlights for Q2 2025. XPOVIO web product income was once $29.7 million this quarter, up 6% from the second one quarter of 2024. Call for for XPOVIO was once constant in the second one quarter of 2025 as opposed to the second one quarter of 2024, with the network atmosphere proceeding to power roughly 60% of overall U.S. gross sales. As everyone knows, the a couple of myeloma marketplace is very aggressive and is changing into extra aggressive every 12 months.

Inside of this marketplace, XPOVIO is situated in the neighborhood as a versatile remedy with a differentiated mechanism of motion, oral handy possibility following medicine with an anti-CD38 remedy in addition to in sufferers who can’t get right of entry to or fail a T mobile enticing remedy. Within the instructional atmosphere, XPOVIO is being increasingly more used earlier than and following T mobile treatments. Taking our effects for the primary part of the 12 months under consideration, together with the ordinary stage of returns within the first quarter of this 12 months, we predict web product income for complete 12 months 2025 can be within the vary of $110 million to $120 million.

After all, we proceed to increase world affected person get right of entry to to selinexor and at the moment are authorized in quite a lot of indications in 50 nations. That is translating into enlargement in royalty income from Menarini, Antengene and different global companions. Royalty income larger 28% to $1.6 million in the second one quarter of 2025 in comparison to the second one quarter of 2024, reflecting larger world call for for XPOVIO and NEXPOVIO. With knowledge from a Section III SENTRY trial in sight, our business staff is making ready for an excessively fast release in myelofibrosis, if authorized. As defined on Slide 23, we proceed to imagine that our height annual income alternative within the U.S. on my own is as much as roughly $1 billion with further royalty and milestone income globally.

As you take into consideration this chance, remember the fact that the typical real- international period for the present same old of care is roughly 13 months. And given the information we have now reported to this point, we imagine we could have a possibility to increase this additional when ruxolitinib is blended with selinexor. On Slide 24, we define why we imagine we’re smartly situated for a fast release in myelofibrosis pending certain knowledge and approval. As we’ve got shared up to now, 75% of the physicians that we surveyed say that they intend to undertake a mixture remedy in myelofibrosis if one turns into to be had. If selinexor is authorized together with ruxolitinib, we might be the primary aggregate remedy in the marketplace.

We might be an all oral remedy, which makes adoption a lot more straightforward, particularly in the neighborhood atmosphere. In this level, there’s an 80% overlap in the neighborhood between myelofibrosis and a couple of myeloma prescribers that our group is already calling on, which permits us to power a fast release and minimizes the prematurely funding required for the release. After all, in endometrial most cancers, as proven on Slide 25, we proceed to imagine that we have got an important alternative within the p53 wild kind and pMMR affected person inhabitants, which represents roughly 50% of complex or recurrent endometrial most cancers sufferers.

Very similar to what I defined from myelofibrosis, there’s a huge overlap between the prospective community-based oncologists taking care of endometrial most cancers sufferers and the ones we’re already enticing with. Now I will flip the decision over to Lori.

Lori A. Macomber: Just right morning, everybody, and thanks, Sohanya. Turning to our financials. Since we issued a press unencumber previous these days with the entire monetary effects, I will be able to center of attention at the highlights and reviewing our steerage for 2025 on Slide 27. Overall income for the second one quarter of 2025 was once $37.9 million in comparison to $42.8 million for the second one quarter of 2024. The decline was once essentially on account of $6 million of nonrecurring license comparable income from our companions identified right through the second one quarter of 2024. U.S. XPOVIO web product income for the second one quarter of 2025 was once $29.7 million in comparison to $28 million for the second one quarter of 2024.

As anticipated, the speed of product returns this quarter reverted to ancient ranges following the ordinary building up reported within the first quarter of this 12 months. Because of this, the gross to web provisions for XPOVIO in the second one quarter have been 26.8%, down from the 45% that we reported within the first quarter of this 12 months and down from 29.3% in the second one quarter of 2024. The year-over-year decline was once essentially pushed through combine and decrease 340B reductions in the second one quarter of 2025. We think our gross to web provisions will stay rather in line with Q2 2025 for the rest of the 12 months.

R&D bills for the second one quarter of 2025 have been $32.8 million, down 15% when in comparison to $38.4 million for the second one quarter of 2024. The lower was once because of a discount in head depend and contractors associated with our value optimization tasks blended with decrease scientific trial and comparable prices essentially from our Section III scientific trial in a couple of myeloma. SG&A bills for the second one quarter of 2025 have been $28.5 million, down 8% when in comparison to $31.1 million for the second one quarter of 2024. The lower was once essentially because of the belief of up to now applied value relief tasks. Hobby expense was once $11.2 million in the second one quarter of 2025, up from $8.9 million in the second one quarter of 2024.

As a reminder, we introduced a refinancing in the second one quarter of 2024 that raised passion expense. Alternatively, there was once just a partial quarter have an effect on in the second one quarter of 2024. Closing 12 months’s refinancing additionally led to a $44.7 million achieve at the extinguishment of debt in the second one quarter of 2024. Different expense was once $2.2 million in the second one quarter of 2025 in comparison to $14.3 million of alternative source of revenue in the second one quarter of 2024. Those quantities have been on account of reoccurring noncash honest price remeasurements of embedded derivatives and legal responsibility categorised commonplace inventory warrants associated with the refinancing transactions in the second one quarter of 2024.

We reported a web lack of $37.3 million or $4.32 in keeping with proportion on a GAAP foundation. This determine comprises $11.2 million in passion expense associated with our debt tools in addition to roughly $2 million in noncash losses from the remeasurement of embedded derivatives and legal responsibility categorised commonplace inventory warrants. Our web loss from operations was once $24.5 million for the second one quarter of 2025. This running consequence displays the efficiency of our core trade right through the quarter. From an income in keeping with proportion viewpoint, our GAAP EPS comprises each passion expense and mark-to-market have an effect on of the warrant and spinoff remeasurement. We proceed to be very diligent in allocating our assets and pipeline prioritization.

We introduced a more or less 20% relief in our personnel in early July. You’re going to begin to see the monetary have an effect on of those movements once we record our effects for the fourth quarter of this 12 months. In 2026, we predict those movements to decrease our annual spend through roughly $13 million. We exited the second one quarter of 2025 with money, money equivalents, limited money and investments of $52 million in comparison to $109.1 million as of December 31, 2024. In accordance with our present running plans, our steerage for the entire 12 months of 2025 is as follows: overall income of $140 million to $155 million, consisting of U.S.

XPOVIO web product income and license, royalty and milestone income anticipated to be earned from our companions, essentially Menarini and Antengene. U.S. XPOVIO web product income to be within the vary of $110 million to $120 million. R&D and SG&A bills to be within the vary of $240 million to $250 million. And in any case, we predict our current liquidity, together with the income we predict to generate from XPOVIO web gross sales in addition to income generated from our license agreements. We’re going to be enough to fund our deliberate operations to the October 15 adulthood of our senior convertible notes. Except the remainder $24.5 million 2025 notes adulthood, and $25 million minimal liquidity covenant.

We think that our liquidity is enough to fund our deliberate operations into January 2026. As we deal with this, we’re operating carefully with our advisers, together with Centerview Companions to discover possible financing and strategic possible choices to give a boost to liquidity and maximize price. I will be able to now flip the decision again to Richard for some ultimate ideas.

Richard A. Paulson: Thanks, Lori. Turning to Slide 29. We proceed to imagine that myelofibrosis in endometrial most cancers, relying at the knowledge from our ongoing Section III scientific trials are each game-changing alternatives for sufferers and our group. With the myelofibrosis alternative on my own, representing as much as a possible $1 billion in height annual income within the U.S. on my own. To ship on those alternatives, we’re operating with urgency and self-discipline to deal with our liquidity whilst retaining our center of attention squarely at the alternative in entrance folks to convey significant, a lot wanted innovation to sufferers and generate vital price. I would love to thank our workers, our companions and our buyers for his or her endured make stronger and trust in our possible.

We sit up for updating you on our growth within the coming months. And I’d now like to invite the operator to open the decision as much as the Q&A portion of these days’s name. Operator?

Operator: [Operator Instructions] With that, our first query comes from the road of Ted Tenthoff with Piper Sandler.

Edward Andrew Tenthoff: I suppose one largest query has to do — truly 2, if I would possibly. First, simply on myelofibrosis, the whole lot appears to be pointing in the suitable route. What is your largest fear about that possible readout? Is it Jakafi doing higher? Is there what might be more or less the snake hiding within the pushes or the graphs or no matter that might wonder us? After which the second one query is solely with truly 3 giant readouts subsequent 12 months with myelofibrosis, the XPORT-MM-031 trial and likewise endometrial. How are you making plans on type of prepping and being able for all of the ones knowledge readouts on the identical time? Is that going to reason any issues simply with regards to processing the whole lot?

Richard A. Paulson: Sure. Thank you, Ted. A few nice questions. I will take the second first, and that’s the reason a superb opportunity that we are occupied with to have 3 giant readouts in entrance folks and to be getting able for probably certain knowledge throughout all the ones readouts is what we are tremendous occupied with as a company. Clearly, construction at the basis in a couple of myeloma, I feel that is one thing which is more or less our bread and butter group is truly able for. Myelofibrosis is a key house for us, clearly, and you may have heard us communicate, and we talked once more these days that there’s vital overlap within the prescriber base.

So so that you could construct on our basis, leverage our business functions and get out and get started having the ability to get able for myelofibrosis and in the end launching it. Pending certain knowledge, once more, I feel we are smartly able for. After which endometrial most cancers more or less in large part the similar. There is numerous overlap as a result of a lot of those sufferers, each in myelofibrosis and endometrial most cancers are observed in the neighborhood. So our group, our payer functions, our scientific affairs functions, our business functions, all have numerous synergy so that you could convey each myelofibrosis and endometrial most cancers to sufferers unexpectedly. In order that’s a excellent downside that we are occupied with.

And the group already is beginning to paintings on getting able for myelofibrosis, clearly, is our subsequent probably transformative alternative and we are shopping ahead to updating you extra at the long run. And for the second one a part of the query, I will flip that over to Reshma to more or less communicate with you about MF.

Our — and discuss our largest fear, I feel there is simply — extensively I will say it is only a prime stage of pleasure, truly a prime stage of pleasure that we are construction at the basis that is been installed position with ruxolitinib and so so that you could probably mix with the usual of care, and create a brand new same old of deal with sufferers, clearly, could be very thrilling for us, particularly for the reason that’s an all-oral with 2 already authorized medicines. However I will let Reshma perhaps proportion with you what her largest fear is relating to shopping on the Section III readout with selinexor and ruxolitinib.

Reshma Rangwala: Sure. Thank you, Richard, and thank you, Ted, for the query. It is attention-grabbing. Fear, I am not positive I’d sofa it in the ones phrases. As Richard was once bringing up, proper, we’ve got been exploring myelofibrosis for such a lot of years. I imply, 7-plus years, each with preclinical knowledge, clearly, teasing aside the mechanism. We have now were given a couple of scientific knowledge units. We have now were given a Section I find out about comparing the mix on this related affected person inhabitants of JAK-naive myelofibrosis. And I’ve to mention I love what we’ve got were given, proper? We have now proven some very, very compelling SVR knowledge, SVR35 at week 24 that greater than doubles what we’ve got noticed with ancient ruxolitinib that results in SVR charges and handiest roughly 1/3 of all sufferers even with symptom development.

And I will admit, proper, symptom development has been the Achilles heel of such a lot of Section III trials. With that mentioned, I love the information that we’ve got noticed to this point, each from a TSS50 viewpoint, but in addition an absolute TSS, that ladder which presentations an 18.5 level development at week 24 relative to baseline. And once more, I all the time contextualize that with one of the vital monotherapy knowledge that still presentations some very compelling TSS knowledge as smartly. However past that, proper, SVR and TSS are handiest 2 the important thing hallmarks that we review in myelofibrosis.

I truly am rather inspired through the illness amendment knowledge, each with the cytokines in addition to bone marrow fibrosis, clearly, the have an effect on on hemoglobin stabilization, this truly intriguing statement that we are additionally together with making improvements to the protection, particularly the Grade 3 plus anemia charges relative to ancient keep watch over.

So I feel like after I step again, proper, I imply, the Section III goes to be the Section III, however I feel going into that Section III, I truly, once more, like what we see in that the mix truly can meaningfully toughen on no longer handiest the important thing endpoints of SVR35 and absolute TSS, however the entire spaces that clearly are very related to the affected person in addition to their doctor.

Edward Andrew Tenthoff: That is very useful. And I proportion your enthusiasm. So I am shopping ahead to the information readouts.

Operator: And your subsequent query comes from the road of Colleen Kusy with Baird.

Colleen Margaret Kusy: Useful replace at the baseline traits for the pivotal MF combo find out about? You spoke to better TSS at baseline. Are you able to discuss that slightly bit extra on the way you suppose that may have an effect on your effects and in particular, have you ever observed a ceiling impact with different trials?

Reshma Rangwala: Sure. Thank you, Colleen. Nice query. So one of the vital knowledge, particularly once we have a look at ancient trials on this JAK-naive myelofibrosis, it does simply whether or not you are looking at TSS50 or absolute TSS that the upper the baseline, proper, the much more likely you will see that significant result, both a 50% development or that share of sufferers who can reach that fifty% development? Or total, that moderate relief in that imply TSS at week 24 relative to baseline. So the upper you’ll push it, the much more likely once more, you’ll reach a significant result. And so once more, those are simply initial traits. We’ve no longer enrolled all of our sufferers.

So in the end, once we whole enrollment, we’re going to take a snapshot of the place that baseline TSS is. However I am truly inspired the place that — the place the evolution has been inside the Section III trial, i.e., once more, pushing to better baseline TSS. So sure, excited to look the place we’re at this time.

Colleen Margaret Kusy: K. And one fast follow-up, if I will. You touched in this slightly bit, however are you able to simply additional give an explanation for the explanation once more for why you suppose you might be seeing the decrease charges of Grade 3/4 anemia with the mix? And the way essential do you suppose that can be for physicians and possible uptake of the mix?

Reshma Rangwala: Sure. It is a truly, truly intriguing statement. And I truly do suppose that it is most probably because of the illness amendment that is happening with selinexor plus ruxolitinib. We have now touched upon some truly compelling cytokine knowledge. This was once again at EHA in June once we checked out selinexor as a monotherapy in that in the past handled inhabitants, what the ones knowledge steered is that it is lowering key cytokines which might be curious about all facets of anemia, in particular hepcidin, ferritin, and many others, proper? You spot decreases in the ones charges. Clearly, or probably might be translating to decrease grade 3 plus anemia.

I am truly liking with what we see from the very initial knowledge popping out of the bone marrow fibrosis, too, a truly marked lower in that reticulin density. It suggests that you are clearing out that marrow. And probably taking into account some repopulation of the ones key cells that in the end can put produce erythrocytes and result in upper hemoglobin. In order that additionally may no longer handiest result in efficacy, i.e., upper hemoglobin, but in addition probably translate to decrease grade 3-plus charges. Early days, proper, those are simply hypothesis-generating knowledge. However I really like the truth that we see those scientific results married with those illness amendment knowledge that once more can give an explanation for each the efficacy and protection facets that we see in our trials.

Operator: And your subsequent query comes from the road of Peter Lawson with Barclays.

Peter Richard Lawson: And simply as we take into consideration revenues and more or less the drivers, what was once the contribution? I could have overlooked this quantity pricing as opposed to stock? After which how must we take into consideration that for the remainder of the 12 months? After which I’ve a follow-up.

Richard A. Paulson: Sure. Thank you, Peter. Stock was once rather constant around the duration. So I feel as Sohanya shared, there is a stability, we noticed an development within the GTN. And that’s the reason one thing that we clearly talked to closing quarter once we had this onetime returns factor. And so total, we even have observed call for to be rather constant. In order that’s more or less the stability within the drivers.

Peter Richard Lawson: Nice. After which that early blinded protection knowledge appears to be like truly encouraging for decrease grade 3 anemia and discontinuation charges as opposed to ruxolitinib. How assured are you that the ones more or less taking flight of knowledge units will more or less hang as soon as it is unblinded?

Reshma Rangwala: It is a excellent query. And Peter, I all the time say, I want I had that best possible crystal ball. Every now and then crystal balls may also be fuzzy. However with that mentioned, I just like the evolution that we’ve got observed in those blinded protection knowledge. We have now taken a few snapshots. So we’ve got taken good thing about those 61 sufferers. They once more have been incorporated as a part of that futility research that the Information Protection Tracking Board evaluated previous this 12 months with roughly 6 months of follow-up, we see a truly great evolution in that protection profile, particularly once we extrapolate with ancient ruxolitinib.

And once we proceed to stick to the ones sufferers and took an up to date snapshot as of July 1, we truly see a equivalent more or less pattern. Sure, numerically, we do see will increase in a few of these charges of AEs, whether or not it is all grade or grade 3 plus, however a truly great in comparison to ancient ruxolitinib. I feel one of the crucial key issues, after I do those extrapolations or I must say, we, as a staff, do those extrapolations, is that ancient ruxolitinib protection knowledge has been rather constant, proper? So once we have a look at the MANIFEST Section III trial as opposed to the COMFORT proper? They span greater than a decade.

And but, once more, it is attention-grabbing to look that, that ruxolitinib protection knowledge through and big, could be very constant. So it lets in us or it offers us slightly bit extra self belief once we extrapolate to what the mix is most likely going to look as rather strong. So in the end, we’re going to want to simply see what the Section III knowledge show. However once more, inspired through this initial statement.

Operator: And your subsequent query comes from the road of Maury Raycroft with Jefferies.

Yichun Qian: That is Amy on for Maury. Congrats at the quarter. I’ve 2 questions, one at the endometrial, the opposite at the SENTRY-2 find out about. So for the endometrial Section III, are you able to communicate in regards to the enrollment growth to this point? And what number of the objective has already been enrolled? And for the SENTRY-2, may you lend a hand us know the way the protocol modification would lend a hand with enrollment of the find out about, taking into consideration the Section III SENTRY and this authentic SENTRY-2 aren’t in the similar inhabitants? And what’s the bar for good fortune now for this amended find out about? And would you propose to turn within the peak line? And the way must we contextualize the information with the brand new inhabitants?

Reshma Rangwala: Sure. Thank you, Amy. So I will take the primary one. For endometrial most cancers, so enrollment could be very secure, proper? It is a distinctive find out about in that it is a biomarker-driven repairs find out about. What we’re seeing at this time and aiming to finish is that what we name the highest of the funnel, i.e., the choice of sufferers who’ve submitted samples to Basis Medication for review in their p53 standing. We see great flows of samples into that bucket and look forward to peak line effects in the midst of 2026. So once more, very inspired through the growth made to this point. We’ve no longer launched any goal enrollment as of these days. So we are not giving out any numbers once more.

We are assured with what we’re seeing on the peak of the funnel in addition to the following randomization that we’re going to hit peak line effects in the midst of 2026. In the case of SENTRY-2, so any other excellent query. So let me simply again up for a minute. So SENTRY-2 was once additionally shopping at that JAK- naive myelofibrosis affected person inhabitants, we are comparing selinexor as a monotherapy in one arm cohort on this inhabitants. Now remember the fact that the inhabitants were other and nonetheless is other than our aggregate trial SENTRY, the continuing Section III in large part founded upon their platelet counts. So SENTRY-2 is solely enrolling sufferers who’ve baseline platelet counts between 50 and 100.

SENTRY is enrolling sufferers with 100 and above. What we plan to do, so this hasn’t came about but, however what we plan to do is to amend the trial to permit all sufferers with baseline platelet counts of fifty the entire means, there is no restrict to sign up as a part of this trial. So now that we’re opening up that baseline platelet cap, we do look forward to that the enrollment goes to select up relative to what we’ve got observed to this point. In the case of the bar, so for the reason that modification has no longer been issued but, we do not see any distinction within the bar.

So we do look forward to that almost all of the sufferers enrolled is a part of the 60-milligram cohort are nonetheless going to be that reasonable thrombocytopenia inhabitants, 50 to 100. It is a very prime unmet want, small inhabitants at roughly 14%. As a result of there is no longer truly efficient treatments for that inhabitants, that bar is any place above 25%, proper, 25% to 30% relative to ancient controls of roughly 15%.

Operator: And your subsequent query comes from the road of Brian Abrahams with RBC Capital Markets.

Brian Corey Abrahams: I suppose perhaps asking a security query slightly little bit of a distinct means. I am curious, like what is your view as to what the prospective the reason why you might be seeing this conceivable total distinction in tolerability whilst you more or less have a look at the ones extrapolated protection charges as opposed to the Section I? Is there the rest you’ll let us know about using antiemetics within the find out about, whether or not sufferers are proceeding to make use of them or preventing after the ones first 2 obligatory cycles? After which my 2nd query is there is been some contemporary adjustments in FDA management at SEDAR.

And I am curious in case you had any up to date communications with the company since your alignment at the new co-primary endpoints for the Section III and your stage of self belief that they are situated on what is going to be required stays the similar as your prior comments?

Reshma Rangwala: Thank you, Brian, for the query. So it truly is a really nice evolution each to ancient ruxolitinib, however as you discussed, additionally to the Section I knowledge. And arguably, I feel one of the vital largest get advantages is across the GI toxicity. It is very widely known with selinexor. However what we see in our Section III extrapolated knowledge is a truly great development each with that nausea in addition to vomiting. So in that Section I, sure, we noticed 80% of the sufferers revel in any grade nausea, roughly 50% of the sufferers experiencing any grade vomiting.

And what we at the moment are probably seeing in our Section III is relief in each the nausea and vomiting from 80% to 64%, even vomiting from 50% to now just about what you notice and be expecting with ancient ruxolitinib round 10%, 12%. I feel you hit the hammer at the head, why can we see this? I feel it is truly as a result of the entire antiemetics. So in our Section I antiemetic utilization was once no longer constant. So there was once many sufferers, sadly, who didn’t take twin antiemetics. There have been rather a couple of sufferers who handiest took one. They have been some sufferers who did not take any. In our Section III, we’ve got truly tightened that requirement.

Just about all of the ones sufferers above 90% are taking the ones twin antiemetics for the primary 2 cycles after which its not obligatory thereafter. And I feel it is as a result of the ones required twin antiemetics, we see this development in nausea, however I feel the truly great development is once more in that vomiting, about from 50% the entire means down to ten%. So a truly great development, no longer handiest to the Section I, however once more additionally relative to ancient ruxolitinib. In the case of the FDA, sure, so quite a lot of evolution occurring with the FDA, as everyone knows. With that mentioned, no further comments.

So we were given that comments again within the 3rd quarter of 2024 across the endpoint alternate and feature no longer gotten any further comments as a result of the whole lot is so documented, we really feel assured within the place that the FDA will in the end tackle our Section III once we meet with, with a bit of luck, subsequent 12 months.

Richard A. Paulson: And Brian, I feel — and simply so as to add to that, I feel once we have a look at the company, I feel we really feel we are truly certain in regards to the evolutions and the way they are keen on accelerating get right of entry to to significant remedies, therapies. And diagnostics and simply a few months again, we participated in a truly treasured CEO listening excursion with the commissioner and truly admire the interactions, I feel within the evolution. So proceeding to sit up for operating certain with them to convey new drugs to sufferers.

Operator: And your subsequent query comes from the road of Jonathan Chang with Leerink Companions.

Wei Ji Chang: Are you able to speak about the situations being explored to give a boost to liquidity and maximize price? What current and/or possible XPOVIO alternatives are being regarded as in those situations?

Richard A. Paulson: Thank you, Jonathan. I imply, on that aspect, there is truly not anything extra so as to add in this level past what we’ve got mentioned in our 8-Ok in July and what we shared these days within the press unencumber and in our 10-Q. As we’ve got mentioned, we’re exploring a complete vary of financing and strategic possible choices which might be going to permit us to increase our money runway or give a boost to liquidity and maximize price. We’ve engaged Centerview Companions, which, as you recognize, is an actual chief on this house to lend a hand us thru this. And we do not intend to speak about or expose any longer trends until and till our Board has authorized an actual explicit motion or another way made up our minds that additional disclosure is acceptable.

In order that’s more or less the place we at the moment are and proceeding to paintings on it, clearly, as we transfer ahead. And clearly, with XPOVIO, it encompasses the totality of XPOVIO.

Operator: And I am appearing no additional questions right now. I want to flip it again to Richard Paulson for last remarks.

Richard A. Paulson: Thank you, operator. I feel as you heard these days, our group could be very keen on handing over at the alternatives in entrance folks. As we’ve got mentioned, we are operating with genuine urgency and with self-discipline to deal with our liquidity and retaining our center of attention squarely at the alternatives we have now in entrance folks, which is why we do what we do each day, and that’s the reason to convey significant a lot wanted innovation to sufferers and to generate vital price. So as soon as once more, I would love to thank our workers, our companions, our buyers for his or her endured make stronger and the realization in our possible and thanks for becoming a member of the decision these days.

Operator: Thanks, presenters. And women and gents, this concludes these days’s convention name. Thanks concerned with becoming a member of. You might now disconnect.